The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: A pilot randomized, placebo-controlled clinical trial
Background and Aim: The metabolic syndrome (MetS) is a pathological condition comprised of abdominal obesity, insulin resistance, hypertension and hyperlipidemia. It has become a major threat globally, resulting in rapidly increasing rates of diabetes, coronary heart disease and stroke. The polyphenol resveratrol (RES) is believed to improve glucose homeostasis and insulin resistance by activating sirtuin, which acetylates and co-activates downstream targets and affects glucose and lipid homeostasis in the liver, insulin secretion in the pancreas, and glucose uptake in skeletal muscle. We studied the effects of RES on insulin resistance, glucose homeostasis and concomitant effects on adipose tissue metabolism and fecal microbiota in insulin resistant subjects with the metabolic syndrome.
Methods: Twenty-eight obese men with the metabolic syndrome were studied during a 35-day stay in the Rockefeller University Hospital metabolic unit. Subjects were randomized to receive resveratrol 1 gram orally twice daily or placebo, while kept weight stable and consuming a Western style diet. At baseline, and after 30 days of resveratrol or placebo administration, subjects underwent testing that included a euglycemic, hyperinsulinemic clamp, 2- hour oral glucose tolerance test, resting energy expenditure (REE), daily blood pressure monitoring, abdominal adipose tissue biopsy, and fecal and blood collections.
Results: RES induced no changes in insulin resistance, but reduced the 120-minute time point and the area under the curve for glucose concentration in the two-hour glucose tolerance test (GTT). In post hoc analysis, Caucasian subjects showed a significant improvement in insulin sensitivity and glucose homeostasis after GTT, whereas non-Caucasians showed no similar effects. Levels of fasting plasma RES and its primary metabolite dihydroresveratrol (DHR) were variable, and did not explain the racial differences in glucose homeostasis. RES administration to Caucasian subjects lead to an increase in several taxa including Akkermansia mucinophila.
Conclusions: Resveratrol 2 grams administered orally to obese men with metabolic syndrome and insulin resistance marginally altered glucose homeostasis. However, in a small group of Caucasians, insulin resistance and glucose homeostasis improved. No concomitant changes in adipose tissue metabolism occurred, but fecal microbiota showed RES-induced changes.
Relevance for patients: The metabolic syndrome increases the risk of diabetes, heart disease and stroke. A major component of the syndrome is insulin resistance, resulting in systemic inflammation and hyperinsulinemia. The primary treatment consists of lifestyle changes, improved diet and increased physical activity. This is often unsuccessful. In this study, RES was well tolerated. In Caucasian men it significantly improved insulin sensitivity and glucose homeostasis. Similar results were found in studies that consisted exclusively of Caucasian men. However, RES presents a novel addition to the current treatment of the MetS and its sequelae.
[1] Beilby J. Definition of metabolic syndrome: Report of the national heart, lung and blood institute/American heart association conference on scientific issues related to definition. Clin Biochem Rev 2004;25:195-8.
[2] Aguilar M,BhuketT, Torres S, Liu B, WongRJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015;313:1973-4.
[3] Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009;13:1-7.
[4] Johnson AR, Milner JJ, Makowski L. The inflammation highway: Metabolism accelerates inflammatory traffic in obesity. Immunol Rev 2012;249:218-38.
[5] Chen H, Tuck T, Ji X, Zhou X, Kelly G, Cuerrier A, et al. Quality assessment of Japanese knotweed (Fallopia japonica) grown on prince Edward Island as a source of resveratrol. JAgric Food Chem 2013;61:6383-92.
[6] Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005;49:472-81.
[7] Zamora-Ros R, Rothwell JA, Achaintre D, Ferrari P, Boutron-Ruault MC, Mancini FR, et al. Evaluation of urinary resveratrol as a biomarker of dietary resveratrol intake in the European prospective investigation into cancer and nutrition (EPIC) study. Br J Nutr 2017;117:1596-602.
[8] Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.
[9] Fröjdö S, Durand C, Pirola L. Metabolic effects of resveratrol in mammals a link between improved insulin action and aging. CurrAging Sci 2008;1:145-51.
[10] Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42.
[11] Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012;67:1307-12.
[12] Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, et al. Significance of resveratrol in clinical management of chronic diseases. Molecules 2017;22:E1329.
[13] Knop FK, Konings E, Timmers S, Schrauwen P, Holst JJ, Blaak EE, et al. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet Med 2013;30:1214-8.
[14] Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2014;99:1510-9.
[15] Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta 2015;1852:1178-85.
[16] Bode LM, Bunzel D, Huch M, Cho GS, Ruhland D, Bunzel M, et al. In vivo and in vitro metabolism of trans- resveratrol by human gut microbiota. Am J Clin Nutr 2013;97:295-309.
[17] Qiao Y, Sun J, Xia S, Tang X, Shi Y, Le G, et al. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct 2014;5:1241-9.
[18] Chen ML, Yi L, Zhang Y, Zhou X, Ran L, Yang J, et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)- induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio 2016;7:e02210-15.
[19] Ding S, Jiang J, Wang Z, Zhang G, Yin J, Wang X, et al. Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signaling in high-fat diet-fed mice. PeerJ 2018;6:e5173.
[20] Jung MJ, Lee J, Shin NR, Kim MS, Hyun DW, Yun JH, et al. Chronic repression of mTOR complex 2 induces changes in the gut microbiota of diet-induced obese mice. Sci Rep 2016;6:30887.
[21] Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231-7.
[22] Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012;142:1100-100.
[23] Amri A, Chaumeil JC, Sfar S, CharrueauC. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012;158:182-93.
[24] Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011;12:R60.
[25] Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31:814-21.
[26] Andrews S. Fast QC: A Quality Control Tool for High Throughput Sequence Data; 2010. Available from: http:// www.bioinformatics.babraham.ac.uk/projects/fastqc. [Last accessed on 2018 Aug 08].
[27] Martin M. Cutadapt removes adapter sequences from high- throughput sequencing reads. EMB Net J 2011;17:10-2. Available from: http://www.journal.embnet.org/index.php/ embnetjournal/article/view/200/458. [Last accessed on 2018 Aug 08].
[28]Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15-21.
[29]García-Alcalde F, OkonechnikovK, Carbonell J, Cruz LM, Götz S, Tarazona S, et al. Qualimap: Evaluating next- generation sequencing alignment data. Bioinformatics 2012;28:2678-9.
[30]Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014;30:923-30.
[31]McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. NucleicAcids Res 2012;40:4288-97.
[32]Thazhath SS, Wu T, Bound MJ, ChecklinHL, Standfield S, Jones KL, et al. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in Type 2 diabetes: A randomized controlled trial. Am J Clin Nutr 2016;103:66-70.
[33] Kjær TN, Ornstrup MJ, Poulsen MM, Stødkilde- Jørgensen H, Jessen N, Jørgensen JO, et al. No beneficial effects of resveratrol on the metabolic syndrome: A Randomized placebo-controlled clinical trial. J Clin Endocrinol Metab 2017;102:1642-51.
[34] Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, et al. High-dose resveratrol supplementation in obese men: An investigator- initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186-95.
[35] Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in Type 2 diabetes mellitus. Nutr Res 2012;32:537-41.
[36] Crandall JP, BarzilaiN. Exploring the promise of resveratrol: Where do we go from here? Diabetes 2013;62:1022-3.
[37] Korsholm AS, Kjær TN, Ornstrup MJ, Pedersen SB. Comprehensive metabolomic analysis in blood, urine, fat, and muscle in men with metabolic syndrome: A Randomized, placebo-controlled clinical trial on the effects of resveratrol after four months’ treatment. Int J Mol Sci 2017;18:E554.
[38] Frendo-Cumbo S, MacPherson RE, Wright DC. Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. Physiol Rep 2016;4:e12877.
[39] VangO, Ahmad N, Baile CA, Baur JA, Brown K, CsiszarA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One
[40] Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612-22.
[41] Wu C, Hwang SH, Jia Y, Choi J, Kim YJ, Choi D, et al. Olfactory receptor 544 reduces adiposity by steering fuel preference toward fats. J Clin Invest 2017;127:4118-23.
[42] Alberdi G, Rodríguez VM, Miranda J, Macarulla MT, Arias N, Andrés-Lacueva C, et al. Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond) 2011;8:29.
[43] Konings E, Timmers S, Boekschoten MV, Goossens GH, Jocken JW, Afman LA, et al. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int J Obes (Lond) 2014;38:470-3.
[44] Sharma AK, Jaiswal SK, Chaudhary N, Sharma VK. A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota. Sci Rep 2017;7:9751.
[45] Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. Science 2017;356:2770.
[46] Bird JK, Raederstorff D, Weber P, Steinert RE. Cardiovascular and antiobesity effects of resveratrol mediated through the gut microbiota. Adv Nutr 2017;8:839-49.
[47] Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res 2017;179:204-22.
[48] Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol 2014;6:703-13.
[49] CaniPD, deVos WM. Next-generation beneficial microbes: The case of Akkermansia muciniphila. Front Microbiol 2017;8:1765.
[50] Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017;23:107-13.
[51] Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006;444:868-74.
[52] Xia X, Weng J. Targeting metabolic syndrome: Candidate natural agents. J Diabetes 2010;2:243-9.